Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Bertz H et al. – Prophylaxis of acute graft–versus–host disease (aGVHD), while maintaining the graft–versus–leukemia (GVL)/lymphoma effect and preventing severe infectious diseases, remains the main challenge in allogeneic hematopoetic cell transplantation (allo–HCT). The authors demonstrate the feasibility of reducing the dose of alemtuzumab as GVHD–prophylaxis to 10 mg absolute in combination with CsA only for UD transplantation in particular.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address